Lv6
1670 积分 2025-07-08 加入
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
3天前
已完结
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
3天前
已完结
Targeting immune cells in the aged brain reveals that engineered cytokine IL-10 enhances neurogenesis and improves cognition
12天前
已关闭
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
13天前
已完结
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study
13天前
已完结
IGF-1R inhibitors in cancer: A review of available evidence and future outlook
23天前
已完结
Advances of IGF-1R inhibitors in Graves’ ophthalmopathy
23天前
已完结
Interleukin 2-Based Cancer Immunotherapies: The Discovery of Next-Generation Antibody-Cytokine Bispecific Antibody Drug
26天前
已完结
Transferrin Receptor Targeting Chimeras (TransTACs) for Membrane Protein Degradation
1个月前
已完结
Hijacking ERAD for targeted degradation of transmembrane proteins
1个月前
已完结
皖公网安备34019202002308
